In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest Uproar in Generics:180-day Exclusivity

Executive Summary

Legal strategies are getting ever more sophisticated in the war between generics and brand-name companies. Some generics companies are in an uproar about a new wrinkle in their efforts to bring lower-priced drugs to market; because of a series of court decisions that upset an FDA practice, generics companies that are first to file for approval of a drug in which they think the patent may be challenged are entitled to 6 months market exclusivity. Previously, the FDA required a lawsuit to be underway in order for generics companies to get exclusivity, but now, a company can get the exclusivity just by making the claim that they might be subjected to a lawsuit. Generics companies worry that their competitors will take advantage of the policy by rushing to file sub-standard ANDAs just to be able to get the market exclusivity; in addition, they might try to strike deals with brand name companies that would give them a reward for keeping other generics companies off the market entirely.

You may also be interested in...



Zydus Cadila Readies Injectables Push Amid Tepid US Growth Outlook

Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and remdesivir launch looms.

Revlon In COVID-19 Tailspin; E-Commerce, At-Home Beauty Provide Lifts

At-home nail and hair care and e-commerce were bright spots in a numbing second quarter for Revlon, which was hit hard by mass retail and salon channel closures at a time of ongoing transformation.

US FDA, Sponsors Eye Best Practices For Virtual AdComms

Agency has created a centralized team to help review divisions with virtual advisory committee preparations and is trying to notify sponsors earlier in the review process about the need for a panel; sponsors cite importance of having a back channel of communications so team members can communicate with each other while an AdComm is underway.

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel